quinagolide vaginal ring (FE-999051) / Ferring - LARVOL DELTA

Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial. (PubMed, Eur J Obstet Gynecol Reprod Biol) - P2 | "Our primary analysis showed no significant difference between treatment groups in terms of change in total lesion size. Many patients in this study presented with advanced disease, which may be less responsive to quinagolide than highly vascularized superficial lesions, as quinagolide inhibits the VEGF signaling pathway."

Clinical • Journal • Endometriosis • Gynecology • Pain • Women's Health • PRL

RAQUEL: Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain (clinicaltrials.gov) - P2 | N=22 | Completed | Sponsor: Ferring Pharmaceuticals | Active, not recruiting ➔ Completed | Trial completion date: Aug 2023 ➔ Feb 2022

Trial completion • Trial completion date • Endometriosis • Gynecology • Pain • Women's Health • IGF1

RAQUEL: Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain (clinicaltrials.gov) - P2 | N=22 | Active, not recruiting | Sponsor: Ferring Pharmaceuticals | Trial primary completion date: Jul 2023 ➔ Feb 2022

Trial primary completion date • Endometriosis • Gynecology • Pain • IGF1

RAQUEL: Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain (clinicaltrials.gov) - P2; N=22; Active, not recruiting; Sponsor: Ferring Pharmaceuticals; Recruiting ➔ Active, not recruiting; N=280 ➔ 22

Clinical • Enrollment change • Enrollment closed • Endometriosis • Gynecology • Pain • IGF1

QLARITY: Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis (clinicaltrials.gov) - P2; N=67; Completed; Sponsor: Ferring Pharmaceuticals; Active, not recruiting ➔ Completed

Trial completion • Endometriosis • Gynecology • Women's Health • IGF1 • MRI